Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
In a meta-analysis of 18 studies of adults ≥65 with a prognosis of ≤6 months, pooled polypharmacy prevalence was 76% and potentially inappropriate medication prevalence 54%, staying above 50% until the final week of life; heterogeneity was very high (I2 >99%).
Meta-analysisn = 499,853
Yaw et al. Prevalence of polypharmacy and potentially inappropriate prescribing in older adults with a prognosis of 6 months or less: a systematic review and meta-analysisIn 5 trials (110,933 presentations) of suspected heart attack, the 0/1 h troponin pathway did not clearly differ from 0/3 h on 30-day death or new type 1 MI (0.8% vs 1.0%), and did not shorten emergency department stay.
Meta-analysisn = 110,933 presentations
Boeddinghaus et al. Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trialsPooling 27 trials (88,830 people), intensive blood pressure lowering cut cardiovascular events by 15% per 10 mm Hg, with or without chronic kidney disease. It did not change kidney failure risk but raised the risk of eGFR declines of 30% or more.
Meta-analysisn = 88,830
Iatridi et al. Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-AnalysisNetwork meta-analysis of 47 RCTs (75,978 patients) with HFrEF feeding a UK cost-effectiveness model: quadruple therapy (ARNI + β-blocker + MRA + SGLT2i) gave most benefit and was most cost-effective (12.31 QALYs); consistent in Sweden and US.
Meta-analysisn = 75,978
Laborante et al. A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEFSystematic review of 49 studies (23 meta-analysed; n=28,972, mostly COPD): in chronic respiratory disease, metabolic, cardiovascular and mental health comorbidities were linked to shorter 6-min walk distance (MD −34, −27, −30 m, outlier-excluded); very low certainty.
Meta-analysisn = 28,972
Marinho et al. Exercise capacity in chronic respiratory diseases in the context of multimorbidity: A systematic review and meta-analysisMeta-analysis of 22 RCTs (28,112 patients) after elective total hip arthroplasty: DOACs vs LMWH lowered VTE (OR 0.62), mainly DVT, but raised overall bleeding (OR 1.19); no bleeding difference for UK-licensed agents and doses. Reoperation and mortality similar.
Meta-analysisn = 28,112
Mohammad et al. A comparison of the efficacy and safety of direct oral anticoagulants with low molecular weight heparin for venous thromboembolism prophylaxis after total hip arthroplasty : a systematic review and meta-analysisCluster RCT, 43 US general hospitals, 11 760 child admissions (asthma, pneumonia, bronchiolitis): care pathways raised guideline adherence 9.9 percentage points vs waitlist control, secondary: fewer ICU transfers (aOR 0.69); no change in stay or readmission.
RCTn = 11,760 hospital admissions
Kaiser et al. Implementing Respiratory Illness Care Pathways in General Hospitals: A Cluster Randomized TrialIn a reconstructed individual patient data meta-analysis of 56 studies in AML, positive leukaemia stem cell status was associated with worse overall survival at diagnosis (HR 1.96; 7781 patients) and in remission (HR 2.59), and worse event-free survival.
Meta-analysisn = 7,781
Reuvekamp et al. Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysisMeta-analysis of 7 non-randomised real-world studies (7112 infants): maternal RSVpreF vaccination ≥14 days before delivery was associated with 82% effectiveness against RSV LRTI hospitalisation to age 3 months and 78% to 6 months.
Meta-analysisn = 7,112
Batool et al. RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants: A Systematic Review and Meta-AnalysisSystematic review of 11 studies (6 meta-analysed): kidney recipients of HBsAg-positive or viremic donor kidneys had graft survival similar to HBV-negative kidneys at 1, 3 and 5 years (RR 1.00 at 5 years); patient survival comparable; HBV transmission 4.94%.
Meta-analysisn = 3,438
Ahuja et al. Transplantation of Hepatitis B Surface Antigen Positive or Viremic Kidneys: A Systematic Review and Meta-Analysis